PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
−0.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
Market Cap
$671.09M
MomentumView details →
1D Return
−0.27%
YTD Return
+6.77%
RSI (14)
59.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
Market Cap
$671.09M
RSI (14)
59.6
MomentumView details →
1D Return
−0.27%
YTD Return
+6.77%
SummaryUpdated Jun 1, 2026
Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The company went public in October 2022 and focuses on developing genetic therapies using advanced gene editing technology. Prime Medicine represents a next-generation approach to gene editing, building upon the foundation of CRISPR technology to create more precise and versatile genetic modifications for treating various diseases.
Similar companies
Latest newsMore news →
Prime Medicine, Inc. reported a Q2 2026 loss of $0.24 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.41 per share a year ago.29d agoPrime Medicine announced a positive binding resolution of its arbitration with Beam Therapeutics, with the tribunal declaring PM647 within Prime Medicine's field and no monetary damages owed.58d agoPrime Medicine received clearance from New Zealand regulators for a clinical trial application for PM577a in H1069Q-mutated Wilson Disease.78d ago